These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33257497)

  • 21. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Khanna D; Distler O; Avouac J; Behrens F; Clements PJ; Denton C; Foeldvari I; Giannini E; Huscher D; Kowal-Bielecka O; Lovell D; Matucci-Cerinic M; Mayes M; Merkel PA; Nash P; Opitz CF; Pittrow D; Rubin L; Seibold JR; Steen V; Strand CV; Tugwell PS; Varga J; Zink A; Furst DE; ;
    J Rheumatol; 2009 Oct; 36(10):2356-61. PubMed ID: 19820225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative responsiveness of physician/assessor-derived and patient-derived core set measures in rheumatoid arthritis trials.
    Neogi T; Xie H; Felson DT
    J Rheumatol; 2008 May; 35(5):757-62. PubMed ID: 18412313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.
    Becker MO; Dobrota R; Garaiman A; Debelak R; Fligelstone K; Tyrrell Kennedy A; Roennow A; Allanore Y; Carreira PE; Czirják L; Denton CP; Hesselstrand R; Sandqvist G; Kowal-Bielecka O; Bruni C; Matucci-Cerinic M; Mihai C; Gheorghiu AM; Mueller-Ladner U; Sexton J; Kvien TK; Heiberg T; Distler O
    Ann Rheum Dis; 2022 Apr; 81(4):507-515. PubMed ID: 34824049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20.
    Albert DA; Huang G; Dubrow G; Brensinger CM; Berlin JA; Williams HJ
    J Rheumatol; 2004 May; 31(5):856-66. PubMed ID: 15124243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
    Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
    Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
    Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
    J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
    Clements PJ; Seibold JR; Furst DE; Mayes M; White B; Wigley F; Weisman MD; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Wong WK
    Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.
    Ruperto N; Ravelli A; Oliveira S; Alessio M; Mihaylova D; Pasic S; Cortis E; Apaz M; Burgos-Vargas R; Kanakoudi-Tsakalidou F; Norambuena X; Corona F; Gerloni V; Hagelberg S; Aggarwal A; Dolezalova P; Saad CM; Bae SC; Vesely R; Avcin T; Foster H; Duarte C; Herlin T; Horneff G; Lepore L; van Rossum M; Trail L; Pistorio A; Andersson-Gäre B; Giannini EH; Martini A;
    Arthritis Rheum; 2006 Jun; 55(3):355-63. PubMed ID: 16739203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in systemic sclerosis trial design.
    Denton CP
    Semin Arthritis Rheum; 2019 Dec; 49(3S):S3-S7. PubMed ID: 31779848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
    van den Hoogen FH; Boerbooms AM; Swaak AJ; Rasker JJ; van Lier HJ; van de Putte LB
    Br J Rheumatol; 1996 Apr; 35(4):364-72. PubMed ID: 8624641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scope and Consistency of Outcomes Reported in Trials of Patients With Systemic Sclerosis.
    Sumpton D; Bigot A; Sautenet B; Craig JC; Hassett G; Thakkar V; Tugwell P; Tong A
    Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1449-1458. PubMed ID: 31309737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis.
    Pincus T
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S109-13. PubMed ID: 16273794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Nevskaya T; Baron M; Pope JE;
    Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.
    Allanore Y; Distler O; Jagerschmidt A; Illiano S; Ledein L; Boitier E; Agueusop I; Denton CP; Khanna D
    Arthritis Rheumatol; 2018 Oct; 70(10):1634-1643. PubMed ID: 29732731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
    Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
    Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.